Rep. Lisa C. McClain Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Boston Scientific Price Performance

Shares of BSX traded down $0.22 during mid-day trading on Thursday, hitting $101.14. The company’s stock had a trading volume of 5,310,086 shares, compared to its average volume of 8,077,432. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The firm has a market capitalization of $149.93 billion, a P/E ratio of 54.08, a P/E/G ratio of 2.02 and a beta of 0.58. The firm has a 50-day simple moving average of $99.04 and a 200 day simple moving average of $102.29.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 175,782 shares of company stock valued at $17,742,314. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BSX. Needham & Company LLC reiterated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. BTIG Research reaffirmed a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Truist Financial lifted their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, UBS Group increased their price target on shares of Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $123.77.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Sound Income Strategies LLC increased its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Steph & Co. purchased a new position in Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp lifted its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. Finally, 1248 Management LLC purchased a new stake in shares of Boston Scientific in the first quarter worth about $26,000. 89.07% of the stock is owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.